GT Biopharma, Inc.
GTBPAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Aug 7, 2023 |
| EF Hutton | maintain | Hold | Aug 6, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jun 4, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 16, 2023 |
| EF Hutton | maintain | Hold | May 15, 2023 |
| HC Wainwright & Co. | maintain | Buy | Apr 3, 2023 |
| EF Hutton | maintain | Hold | Mar 31, 2023 |
| EF Hutton | maintain | Hold | Jan 5, 2023 |
| HC Wainwright & Co. | maintain | Buy | Sep 12, 2022 |
| HC Wainwright & Co. | maintain | Buy | May 24, 2021 |
| B. Riley Securities | maintain | Buy | Apr 13, 2021 |
| B. Riley FBR | maintain | Buy | Apr 13, 2021 |
| Roth Capital | maintain | Buy | Mar 17, 2021 |
Earnings History
Next report: Nov 13, 2026 · EPS est. $-2.50| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-3.00 | $-2.00 | — | — |
| May 21, 2026 | $-0.11 | $-2.00 | — | — |
| Mar 2, 2026 | $-55.50 | $-5.50 | — | — |
| Nov 13, 2025 | $-0.83 | $-9.50 | — | — |
| Aug 13, 2025 | $-0.55 | $-17.00 | — | — |
| May 21, 2025 | $-0.33 | $-16.00 | — | — |
| Mar 25, 2025 | $-1.67 | $-38.75 | — | — |
| Nov 14, 2024 | $-1.53 | $-2.70 | — | — |
News
SAN FRANCISCO, CALIFORNIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced that it has been selected for an oral presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting taking place from November 4-8, 2026 in Phoenix, AZ.
FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocol Initiation of Phase 1 trial in MM patients contingent upon timing and receipt of non-dilutive grant funding Phase 1 dose escalation basket trial with GTB-5550 in solid tumor patients continues to actively enroll, with an update anticipated in Q4 2026 Unaudited proforma cash balance as of September 15, 2026 of approximately $11 million anticipated to provide sufficient cash runway…
GT Biopharma, Inc. (GTBP) Discusses TriKE Platform, Clinical Progress, and the Case for NK Cell Immunotherapy Transcript
SAN FRANCISCO, CALIFORNIA, Sept. 11, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, will host a live company presentation on the development of the TriKE® platform for cancer treatment today, September 11, 2026, at 2:00 p.m. Eastern Time.
Phase 1 trial evaluating GTB-3650 TriKE ® remains ongoing, with an update anticipated in 2H 2026